Search Results
21 protocol(s) meet the specified criteria
Phase I, Open-Label, Multicenter, Dose-Escalation Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human Ox40l, for Intratumoral Injection to Patients with Advanced Malignancies

Phase I/IB, Open-Label, Multicenter, Dose-Escalation Study of NIS793 in Combination with PDR001 in Adult Patients with Advanced Malignancies

Phase III, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIB/C/D or Stage IV Melanoma

Open-Label, Multicenter Phase IIA Study to Evaluate the Efficacy, Safety, and Immunological Response of OBP-301, Telomerase Specific Replication-Competent Oncolytic Adenovirus in Patients with Unresectable Metastatic Melanoma

Phase I/II Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma

Phase II Neoadjuvant Trial of Nivolumab in Combination with HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1A Melanoma (Neo-NivoHF10)

Multicenter Phase II, Adaptive, Open-Label Trial of Intratumoral pIL-12 plus Electroporation in Combination with Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment

Multi-Tracer PET Assessment of Response in Various Malignancies in Investigational and Recently Approved Therapeutic Agents

Phase IB/II, Multicenter, Trial of Talimogene Laherparepvec in Combination with Pembrolizumab (MK-3475) for Treatment of Unresectable, Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

Registry Study to Evaluate the Survival and Long-Term Safety of Subjects with Melanoma Who Previously Received Talimogene Laherparepvec

Randomized, Phase II Trial of Intermittent versus Continuous Dosing of Dabrafenib and Trametinib in BRAFV600E/K Mutant Melanoma

Prospective, Randomized, Blinded, Placebo-Controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) plus Yeast Cell Wall Particles (YCWP) plus Dendritic Cells (DC) Vaccine versus Unloaded YCWP plus DC in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence

PV-10 versus Systemic Chemotherapy or Intralesional Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma without Distant Metastases

Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

Phase I/II, Open-Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies

Phase IB Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients with Advanced Melanoma

Phase IB, Open-Label, Multicenter, Dose-Escalation Trial of Intratumoral Injections of SD-101 in Combination with Pembrolizumab in Patients with Metastatic Melanoma

Phase II Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Death - 1 (Pd-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma

Phase IB Trial of Neoadjuvant X4P-001 Alone and with Pembrolizumab in Patients with Resectable Melanoma

Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unsectable Desmoplastic Melanoma (DM)